Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. White (Rochester Medical Center, United States of America), C. Vizza (Rome, Italy), C. Blair (Foster City, United States of America), J. Langley (Brentford, United Kingdom), M. Hoeper (Hannover, Germany). Early improvements predict outcomes in pulmonary arterial hypertension. 269

Member's Comments

No comment yet.

Related content which might interest you: Early detection and management of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 306-312 Year: 2012 Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 608-616 Year: 2011 Improving survival in pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 218-220 Year: 2005 Pregnancy outcomes in pulmonary arterial hypertension in the modern management era Source: Eur Respir J 2012; 40: 1304-1305 Year: 2012 Improving patient outcomes in pulmonary hypertension Source: Eur Respir Rev 2015; 24: 550-551 Year: 2015 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension Source: Eur Respir J, 50 (4) 1700465; 10.1183/13993003.00465-2017 Year: 2017 Age, risk and outcomes in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018 Year: 2018 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Renal dysfunction correlates with impaired hemodynamics and unfavorable outcome in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 939-944 Year: 2012 Identification of treatment goals in paediatric pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 1616-1626 Year: 2014 Functional impact of exercise pulmonary hypertension in patients with borderline pulmonary arterial pressure Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017